Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	$ 0	$ 0	$ 0	$ 0
Costs and expenses:
Selling, general and administrative	437,000	242,000	913,000	371,000
Total	437,000	242,000	913,000	371,000
Operating loss	(437,000)	(242,000)	(913,000)	(371,000)
Total other (expense) income
Interest expense	0	0	(1,000)
Income (loss) from investments in unconsolidated entities, net	2,000	(269,000)	4,000	(267,000)
Total other (expense)	2,000	(269,000)	3,000	(267,000)
Loss before income taxes	(435,000)	(511,000)	(910,000)	(638,000)
Reversal of provision for income taxes		0	163,000
Net loss	(435,000)	(511,000)	(747,000)	(638,000)
Net loss attributable to noncontrolling interests	0	77,000	0	96,000
Net loss attributable to U.S. Neurosurgical Holdings, Inc.	$ (435,000)	$ (434,000)	$ (747,000)	$ (542,000)
Basic and diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.03)	$ (0.05)	$ (0.06)	$ (0.07)
Weighted average common shares outstanding, basic and diluted (in shares)	13,484,924	7,892,185	12,692,067	7,892,185